Your shopping cart is currently empty

Pimobendan (UD-CG 115 BS) is a selective inhibitor of PDE3 (IC50: 0.32 μM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $40 | In Stock | In Stock | |
| 10 mg | $56 | In Stock | In Stock | |
| 25 mg | $81 | In Stock | In Stock | |
| 50 mg | $108 | In Stock | In Stock | |
| 100 mg | $147 | In Stock | In Stock | |
| 500 mg | $213 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $61 | In Stock | In Stock |
| Description | Pimobendan (UD-CG 115 BS) is a selective inhibitor of PDE3 (IC50: 0.32 μM). |
| Targets&IC50 | PDE3:0.32 μM |
| In vitro | Compared to the control group, Pimobendan (1 mg/kg) significantly reduced the permeability of cardiomyocytes and also decreased the levels of TNF-α and IL-1β within the chamber without affecting myocardial nerves, heart weight, and body weight. In a mouse model of EMC virus-induced myocarditis, Pimobendan contributed to an extension of lifespan. The final survival rate was significantly increased from 33.6% (control group) to 53.3% (0.1 mg/kg) or 66.7% (1 mg/kg). Additionally, Pimobendan inhibited the expression of inducible nitric oxide synthase genes in the heart, thereby reducing the content of nitric oxide within the heart. |
| In vivo | When administered to human atrial cells, Pimobendan (100 μM) increased the L-type calcium current by 250.4% (EC50: 1.13 μM). Its effect on rabbit atrial cells was significantly lower, resulting in a 67.4% increase in ICa(L). Pimobendan exhibits selective inhibitory action on isolated PDE III in guinea pig myocardium (IC50: 0.32 μM), with much higher IC50s for PDE I and PDE II (>30 μM). It also inhibits cAMP-PDE III activity (IC50: 2.4 μM) and induces a positive inotropic effect on isolated guinea pig papillary muscles (EC50: 6.0 μM), partially due to its selective inhibition of myocardial PDE III. |
| Synonyms | UD-CG115, UD-CG 115 BS, Pimobendane, Acardi |
| Molecular Weight | 334.37 |
| Formula | C19H18N4O2 |
| Cas No. | 74150-27-9 |
| Smiles | CC1C(C=2C=C3C(N=C(N3)C4=CC=C(OC)C=C4)=CC2)=NNC(=O)C1 |
| Relative Density. | 1.36 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (164.49 mM), Sonication is recommended. Ethanol: 5 mg/mL (14.95 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.98 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.